Who, what, when…and especially where: Why care settings matter for representative real-world datasets
A vast majority of cancer patients’ care starts with a visit to a primary care provider for a routine screening or consult for a worrisome symptom. They may visit a local hospital or health system for testing and initial review by a specialist – but from there, the care pathway could take several different routes. […]
COTA and Hackensack Meridian Health at ASCO 2024
Compared to information from clinical trials, real-world data (RWD) provides oncologists and cancer researchers with data on how diverse groups of patients are treated in current clinical practice. Researchers from Hackensack Meridian Health and COTA teamed up to analyze real-world treatment outcomes for people with multiple myeloma – a type of blood cancer. The findings, […]
Introducing CAILIN: The Latest Development from COTA’s AI Lab
At COTA, we know that high-quality oncology real-world data (RWD) holds the keys to the next breakthrough in cancer care. Through our work with life sciences partners, oncologists, and hospitals across the U.S., we’ve seen firsthand how data can power discoveries about new treatments and inform the right steps in care for patients. We also […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
Real-world data is helping to fine-tune care decisions for multiple myeloma patients: New research published at 2024 ASCO Annual Meeting
Researchers and clinicians agree that standards of care should be regularly reviewed and optimized based on the latest evidence to ensure that existing recommendations remain relevant.
Exploring standards of care in real-world settings with RWD
Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers some additional guidance on emerging trends in the oncology community.
From Data to Discovery: How AI Is Accelerating Progress in Oncology
the latest wave of data, technology, and artificial intelligence (AI) advances are challenging views, empowering individuals across life sciences functions to answer research questions using many different types of RWD
How COTA & Komodo Health Combine Real-World Datasets for Better Patient Insights
Komodo Health and COTA teamed up to link COTA’s high-quality oncology data with Komodo’s vast Healthcare MapTM
Getting personal with real-world data at ViVE 2024
At ViVE 2024 in Los Angeles, COTA’s Chief Medical Officer, C.K. Wang, MD will take part in a discussion session called “Data That’s Getting Personal”.
Real world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA)
Amer Methqal Zeidan, Leyla Hernandez Donoso, Sejla Hodzic, Henry F Owusu, Dhrubajyoti Pathak, Summera Qiheng Zhou, Eytan Stein
